What types of cancer does margetuximab mainly treat?

Margetuximab (margetuximab-cmkb) is a targeted immunotherapy drug approved by the US FDA for the treatment of advanced HER2-positive breast cancer . It is specially designed for patients who have progressed after multiple lines of anti-HER2 treatment. The drug is mainly suitable for use in combination with chemotherapy to treat adult patients with metastatic HER2-positive breast cancer who have previously received two or more anti-HER2 treatment regimens (at least one of which is for metastatic disease).

Margetuximab is structurally derived from trastuzumab, but itsFc segment has been engineered and optimized to enhance its affinity with the FcγRIIIa (CD16A) receptor in the immune system, thereby significantly improving antibody-dependent cell-mediated cytotoxicity (ADCC), especially in patients with CD16A low-affinity alleles, showing better efficacy. In the pivotal SOPHIA phase III clinical trial, margetuximab combined with chemotherapy showed a statistically significant improvement in progression-free survival compared with trastuzumab combined with chemotherapy, especially in specific gene subpopulations (such as CD16A F158F genotype), showing a more obvious therapeutic advantage. This shows that margetuximab not only inherits the role of traditional HER2-targeting antibodies in blocking signaling pathways, but also more effectively mobilizes the patient's own immune system to kill tumor cells.

The launch of this drug provides a new treatment option for patients with relapsed or drug-resistant HER2-positive breast cancer, and is particularly suitable for subsequent treatment strategies after failure of trastuzumab or T-DM1 treatment. Although margetuximab is not currently available in mainland China, its clinical experience in Europe and the United States is attracting great attention from the domestic oncology community, and it is expected to become an important player in the personalized treatment of HER2-positive breast cancer in the future.

Reference materials:https://www.margenza.com/